EVK Stock Analysis: Evonik Industries | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 7.400m EUR | 12M Return: -1.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 21.9M
EPS Trend: 43.5%
Qual. Beats: 0
Rev. Trend: -90.6%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Evonik Industries AG is a German specialty chemicals company headquartered in Essen, founded in 1847. It operates globally across Asia-Pacific, Europe, the Middle East, Africa, and the Americas through three reporting segments: Advanced Technologies, Custom Solutions, and Infrastructure.
The Advanced Technologies segment supplies performance chemicals such as medical-grade polymers, hydrogen peroxide (used in semiconductor wafer cleaning and pulp/paper bleaching), specialty silicas and silanes for tires, electronics, and cosmetics, and the essential amino acids D-/L-methionine and lysine for animal feed. Evonik is one of the worlds largest producers of methionine, a key feed additive for poultry and swine, reflecting the companys deep position in life-sciences-oriented specialty chemistry rather than commodity chemicals.
The Custom Solutions segment focuses on functional additives for coatings, adhesives, sealants, polyurethane foams, and lubricants serving cosmetics, cleaning, and pharmaceutical end-markets. The Infrastructure segment supplies C4-based petrochemical intermediates, including butadiene, MTBE, butene-1, isononanol, and DINP, which feed into plastics, packaging, rubber, fuel production, and as plasticizers for the construction and automotive industries.
- Methionine oversupply pressures animal nutrition segment margins
- High European energy costs squeeze German production profitability
- Construction slowdown weakens plasticizer and coatings additives demand
| Net Income: 157.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.10 > 1.0 |
| NWC/Revenue: 13.35% < 20% (prev 14.49%; Δ -1.13% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.39b > Net Income 157.0m |
| Net Debt (4.43b) to EBITDA (1.76b): 2.51 < 3 |
| Current Ratio: 1.51 > 1.5 & < 3 |
| Outstanding Shares: last quarter (466.0m) vs 12m ago 0.0% < -2% |
| Gross Margin: 22.59% > 18% (prev 24.74%; Δ -2.14% > 0.5%) |
| Asset Turnover: 70.91% > 50% (prev 74.79%; Δ -3.88% > 0%) |
| Interest Coverage Ratio: 2.59 > 6 (EBIT TTM 561.0m / Interest Expense TTM 217.0m) |
| A: 0.10 (Total Current Assets 5.43b - Total Current Liabilities 3.60b) / Total Assets 18.5b |
| B: 0.39 (Retained Earnings 7.21b / Total Assets 18.5b) |
| C: 0.03 (EBIT TTM 561.0m / Avg Total Assets 19.3b) |
| D: 0.81 (Book Value of Equity 8.23b / Total Liabilities 10.2b) |
| Altman-Z'' = 2.97 = A |
| DSRI: 1.08 (Receivables 1.82b/1.87b, Revenue 13.7b/15.1b) |
| GMI: 1.09 (GM 24.74% / 22.59%) |
| AQI: 1.01 (AQ_t 0.33 / AQ_t-1 0.33) |
| SGI: 0.91 (Revenue 13.7b / 15.1b) |
| TATA: -0.07 (NI 157.0m - CFO 1.39b) / TA 18.5b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of July 04, 2026, the stock is trading at EUR 16.01 with a total of 859,379 shares traded. Over the past week, the price has changed by +0.06%, over one month by +1.39%, over three months by +1.15% and over the past year by -1.65%.
Current recommended Stop Loss: 15.40 (which is 3.8% or 1.3 ATR below the current price).
Evonik Industries has no consensus analysts rating.
P/E Trailing = 46.7059
P/E Forward = 19.9203
P/S = 0.5394
P/B = 0.906
P/EG = 6.2284
Revenue TTM = 13.7b EUR
EBIT TTM = 561.0m EUR
EBITDA TTM = 1.76b EUR
Long Term Debt = 2.59b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 684.0m EUR (from shortTermDebt, last quarter)
Debt = 5.02b EUR (from shortLongTermDebtTotal, last quarter) + Leases 865.0m
Net Debt = 4.43b EUR (calculated: Debt 5.02b - CCE 589.0m)
Enterprise Value = 11.8b EUR (7.40b + Debt 5.02b - CCE 589.0m)
Interest Coverage Ratio = 2.59 (Ebit TTM 561.0m / Interest Expense TTM 217.0m)
EV/FCF = 19.36x (Enterprise Value 11.8b / FCF TTM 611.0m)
FCF Yield = 5.16% (FCF TTM 611.0m / Enterprise Value 11.8b)
FCF Margin = 4.45% (FCF TTM 611.0m / Revenue TTM 13.7b)
Net Margin = 1.14% (Net Income TTM 157.0m / Revenue TTM 13.7b)
Gross Margin = 22.59% ((Revenue TTM 13.7b - Cost of Revenue TTM 10.6b) / Revenue TTM)
Gross Margin QoQ = 25.21% (prev 20.25%)
Tobins Q-Ratio = 0.64 (Enterprise Value 11.8b / Total Assets 18.5b)
Interest Expense / Debt = 4.32% (Interest Expense 217.0m / Debt 5.02b)
Taxrate = 49.11% (165.0m / 336.0m)
NOPAT = 285.5m (EBIT 561.0m * (1 - 49.11%))
Current Ratio = 1.51 (Total Current Assets 5.43b / Total Current Liabilities 3.60b)
Debt / Equity = 0.61 (Debt 5.02b / totalStockholderEquity, last quarter 8.23b)
Debt / EBITDA = 2.51 (Net Debt 4.43b / EBITDA 1.76b)
Debt / FCF = 7.25 (Net Debt 4.43b / FCF TTM 611.0m)
Total Stockholder Equity = 8.30b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.81% (Net Income 157.0m / Total Assets 18.5b)
RoE = 1.89% (Net Income TTM 157.0m / Total Stockholder Equity 8.30b)
RoCE = 5.15% (EBIT 561.0m / Capital Employed (Equity 8.30b + L.T.Debt 2.59b))
RoIC = 1.91% (NOPAT 285.5m / Invested Capital 15.0b)
WACC = 4.62% (E(7.40b)/V(12.4b) * Re(6.26%) + D(5.02b)/V(12.4b) * Rd(4.32%) * (1-Tc(0.49)))
Discount Rate = 6.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -3.62 | Cagr: 0.0%
[DCF] Terminal Value 73.10% ; FCFF base≈723.8m ; Y1≈634.7m ; Y5≈512.8m
[DCF] Fair Price = 8.16 (EV 8.23b - Net Debt 4.43b = Equity 3.80b / Shares 466.0m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 43.47 | EPS CAGR: 12.31% | SUE: 0.71 | # QB: 0
Revenue Correlation: -90.64 | Revenue CAGR: -5.67% | SUE: -2.07 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.53 | Chg30d=+9.38% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.42 | Chg30d=-3.41% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=1.50 | Chg30d=+3.32% | Revisions=+77% | GrowthEPS=+10.6% | GrowthRev=+3.1%
EPS next Year (2027-12-31): EPS=1.46 | Chg30d=+1.57% | Revisions=+42% | GrowthEPS=-2.9% | GrowthRev=-0.4%
[Analyst] Revisions Ratio: +64% (up=19, down=3)